Results 81 to 90 of about 302,501 (282)

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

The Need for Multiple Naloxone Administrations for Opioid Overdose Reversals: A Review of the Literature

Substance Abuse, 2022
Background A growing challenge in the opioid epidemic is the rise of highly potent synthetic opioids, (i.e., illicitly manufactured fentanyl [IMF]) entering the US non-prescription opioid market. Successful reversal may require multiple doses of naloxone,
Randa Abdelal, A. Banerjee, Suzanne Carlberg-Racich, Neyla Darwaza, D. Ito, J. Epstein   +5 more
semanticscholar   +1 more source

Prescription Sequence Symmetry Analysis of Glucagon‐Like Peptide‐1 Receptor Agonists and Neuropsychiatric Conditions

Clinical Pharmacology &Therapeutics, EarlyView.
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez, Sam Wade, Darshna Goordeen, Jenni Ilomäki, Amanda J. Cross, Monica Langiu, George S. Q. Tan   +6 more
wiley   +1 more source

The political consequences of opioid overdoses

PLOS ONE, 2020
The United States suffered a dramatic and well-documented increase in drug-related deaths from 2000 to 2018, primarily driven by prescription and non-prescription opioids, and concentrated in white and working-class areas. A growing body of research focuses on the causes, both medical and social, of this opioid crisis, but little work as yet on its ...
Aaron R. Kaufman, Eitan D. Hersh
openaire   +4 more sources

Drug use, homelessness and health: responding to the opioid overdose crisis with housing and harm reduction services

Harm Reduction Journal, 2021
Background Canada is in the midst of an opioid overdose crisis and Alberta has one of the highest opioid use rates across the country. Populations made vulnerable through structural inequities who also use opioids, such as those who are unstably housed ...
Katrina Milaney, Jenna Passi, Lisa Zaretsky, Tong Liu, Claire M. O’Gorman, Leslie Hill, Daniel J. Dutton   +6 more
semanticscholar   +1 more source

Effectiveness of direct patient outreach with a narrative naloxone and overdose prevention video to patients prescribed long-term opioid therapy in the USA: the Naloxone Navigator randomised clinical trial

BMJ Public Health
Introduction Public health efforts to reduce opioid overdose fatalities include educating people at risk and expanding access to naloxone, a medication that reverses opioid-induced respiratory depression.
Jason M Glanz, Ingrid A Binswanger, Shane R Mueller, Komal J Narwaney, Nicole M Wagner, Stanley Xu, Courtney R Kraus, Kris Wain, Sheila Botts   +8 more
doaj   +1 more source

3570 The Regulatory Landscape of Products to Treat Opioid Overdose

Journal of Clinical and Translational Science, 2019
OBJECTIVES/SPECIFIC AIMS: Since 1971, Naloxone has been the only FDA approved opioid antagonist indicated for use after opioid overdose. New formulations of Naloxone have been introduced into the market, including an injectable, auto-injector, and nasal ...
Pooja Singh, Kaylene Okada, Amelia Spinrad, Nancy Pire-Smerkanich, Eunjoo Pacifici   +4 more
doaj   +1 more source

Differential expression of NPAS4 in the dorsolateral prefrontal cortex following opioid overdose

Drug and Alcohol Dependence Reports, 2022
Background: Although preclinical models reveal the neurobiological pathways altered through opioid abuse, comprehensive assessments of gene expression in human brain samples are needed.
David W. Sosnowski, Andrew E. Jaffe, Ran Tao, Amy Deep-Soboslay, Chang Shu, Sarven Sabunciyan, Joel E. Kleinman, Thomas M. Hyde, Brion S. Maher   +8 more
doaj   +1 more source

A conceptual model for understanding post-release opioid-related overdose risk

Addiction Science & Clinical Practice, 2019
Post-release opioid-related overdose mortality is the leading cause of death among people released from jails or prisons (PRJP). Informed by the proximate determinants framework, this paper presents the Post-Release Opioid-Related Overdose Risk Model. It
Paul J. Joudrey, Maria R. Khan, Emily A. Wang, Joy D. Scheidell, E. Jennifer Edelman, D. Keith McInnes, Aaron D. Fox   +6 more
doaj   +1 more source

“I don’t go to funerals anymore”: how people who use opioids grieve drug-related death in the US overdose epidemic

Harm Reduction Journal, 2022
Background Opioid-related overdose death is a public health epidemic in much of the USA, yet little is known about how people who use opioids (PWUO) experience overdose deaths in their social networks.
Allison V. Schlosser, Lee D. Hoffer
doaj   +1 more source